Low basal levels of circulating adiponectin in patients undergoing coronary stenting predict in-stent restenosis, independently of basal levels of inflammatory markers: Lipoprotein associated phospholipase A2, and myeloperoxidase

Clinical Biochemistry

Volumn 41, Issue 18, 2008, Pages 1429-1433

  Moldoveanu, Elena ^a,b   Mut Vitcu, Bogdan ^c   Tanaseanu, George R ^d   Marta, Daciana S ^a   Manea, Gabriela ^a,b   Kosaka, Tetsuya ^e   Vidulescu, Cristina ^d   Tanaseanu, Cristina ^d  

^a VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^b TITU MAIORESCU UNIVERSITY   (Romania)

^c Institute of Cardiovascular Diseases   (Romania)

^d CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e Alfresa Pharma Corporation   (Japan)

Author keywords

Adiponectin; In stent restenosis; Lipoprotein associated phospholipase A2; Myeloperoxidase

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADIPONECTIN; MYELOPEROXIDASE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DISEASE MARKER; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; IN-STENT RESTENOSIS; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL;

EID: 55949108385     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.09.109     Document Type: Article

References (26)

1. Butany J., Carmichael K., Leong S.W., and Collins M.J. Coronary artery stents: identification and evaluation. J Clin. Pathol 58 (2005) 795-804
2. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
3. Park D.W., Hong M.K., Suh I.W., et al. Results and predictors of angiographic restenosis and long term adverse cardiac events after drug eluting stent implantation for aorto-ostial coronary artery disease. Am j Cardiol 99 6 (2007) 760-765
4. Bavry A.A., Kumbhani D.J., Helton T.J., Borek P.P., Mood G.R., and Bhatt D.L. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 119 (2006) 1056-1061
5. Assali A.R., Moustapha A., Sdringola S., et al. Acute coronary syndrome may occur with in-stent restenosis and is associated with adverse outcomes (the PRESTO trial). Am J Cardiol 98 (2006) 729-733
6. Spagnoli L.G., Bonanno E., Sangiorgi G., and Mauriello A. Role of inflammation in atherosclerosis. J Nucl Med 48 (2007) 1800-1815
7. Matsuzawa Y. Adiponectin. Identification physiology and clinical relevance in metabolic and vascular disease. Atherosclerosis Supplements 6 (2005) 7-14
8. Tanaseanu C., Moldoveanu E., Kosaka T., Tanaseanu S., Neagu M., and Popescu L.M. The significance of human platelet-activating factor-acetylhydrolase in patients with chronic stable angina. Eur J Intern Med 15 5 (2004) 291-297
9. Oei H.H., van der Meer I.M., Hofman A., et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 11 (2005) 570-575
10. Corson M.A., Jones P.H., and Davidson M.H. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol 101 suppl (2008) 41F-50F
11. Anderson J.L. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol 101 suppl (2008) 23F-33F
12. Lerman A., and McConnell J.P. Lipoprotein-associated phospholipase A2: a risk marker or a risk factor?. Am J Cardiol 101 suppl (2008) 11F-22F
13. Davidson M.H., Corson M.A., Alberts M.J., et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 101 suppl (2008) 51F-57F
14. Zhang R., Brennan M.L., Fu X., et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286 (2001) 2136-2142
15. Vasilyev N., Williams T., Brennan M.L., et al. Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation 112 (2005) 2812-2820
16. Kosaka T., Yamaguchi M., Soda Y., et al. Spectrophotometric assay for serum platelet-activating factor acetylhydrolase activity. Clin Chim Acta 296 1-2 (2000) 151-161
17. Buchmann R., Hasilik A., Van Dyke T.E., and Lange D.E. Amplified crevicular leukocyte activity in aggressive periodontal disease. J Dent Res 81 (2002) 716-721
18. Sinha M.K., Vazquez J.M., Calvino R., Gaze D.C., Collinson P.O., and Kaski J.C. Effects of balloon occlusion during percutaneous coronary intervention on circulating ischemia modified albumin and transmyocardial lactate extraction. Heart 92 (2006) 1852-1853
19. Tao L., Gao E., Jiao X., et al. Adiponectin cardioprotection after myocardial ischemia/ reperfusion involves the reduction of oxidative/nitrative stress. Circulation 115 (2007) 1408-1416
20. Okomoto Y., Arita Y., Nishida M., et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 32 (2000) 47-50
21. Okamoto M.Y., Kihara S., Ouchi N., et al. Adiponectin reduces atherosclerosis in apolipoprotein E-Deficient. Circulation 106 (2002) 2767-2770
22. Wang Y., Lam K.S.L., Xu J.Y., et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization dependent manner. J Biol Chem 280 (2005) 18341-18347
23. Shimada K., Miyauchi K., Moruno H., et al. Predictive value of the adipocyte-derived plasma protein adiponectin for restenosis after elective coronary stenting. Jpn Heart J 43 (2002) 85-91
24. Inami N., Nomura S., Shimazu T., Manabe K., Kimura Y., and Iwasaka T. Adiponectin incompletely prevent MCP-1-dependent restenosis after percutaneous coronary intervention [corrected] in patients with coronary artery disease. J Thromb Thrombolysis 24 3 (2007) 267-273
25. Kitta Y., Takano H., Nakamura T., et al. Low adiponectin levels predict late in-stent restenosis after bare metal stenting in native coronary arteries. Int J Cardiol (2007) 10.1016/j.ijcard.2007.09.004
26. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adipose specific protein, adiponectin, in obesity. Biochem Biophys Res Comm 257 (1999) 79-83